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Background: Cell assisted lipotransfer serves as a novel technique
for both breast reconstruction and breast augmentation. This
systematic review assesses the efﬁcacy, safety and use of patient
reported outcome measures in studies involving cell assisted lip-
otransfer. We also carry out an objective assessment of study
quality focussing on recruitment, follow-up and provide an up-to-
date clinical trial landscaping analysis.
Methods: Key electronic databases were searched according to
PRISMA guidelines and pre-deﬁned inclusion and exclusion
criteria. Two independent reviewers examined the retrieved
publications and performed data extraction.
Results: 3980 publications were identiﬁed. Following screening, 11
studies were included for full review, representing a total of 336
patients with a follow-up time ranging from six to 42 months. A
degree of variation was noted in graft retention and reported
satisfaction levels, although there were only three comparativeversity of St. Andrews, North Haugh, St. Andrews, KY16 9TF, UK.
ad).
ier Ltd on behalf of British Association of Plastic, Reconstructive and Aesthetic
BY license (http://creativecommons.org/licenses/by/4.0/).
Z. Arshad et al. / JPRAS Open 10 (2016) 5e206studies with conﬂicting results. Complications occurred at a rate of
37%. Additionally, there was a paucity of objective outcomes
assessments (e.g. 3D assessment modalities or validated patient
reported outcome measures) in the selected studies.
Conclusions: Cell assisted lipotransfer is a surgical technique that is
currently employed sparingly within the plastic & reconstructive
surgery community. Presently, further technical and outcome
standardization is required, in addition to rigorous randomized
controlled trials and supporting long-term follow-up data to better
determine procedural safety and efﬁcacy. Routine use of more
objective outcome measures, particularly 3D assessments and
validated patient reported outcome measures, will also help
facilitate wider clinical adoption and establish procedural utility.
© 2016 The Author(s). Published by Elsevier Ltd on behalf of British
Association of Plastic, Reconstructive and Aesthetic Surgeons. This
is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).Introduction
Breast augmentationwas themost commonly performed cosmetic procedure in the US in 2014with
over 102,000 procedures taking place.1 Conventionally, implants have been utilized. However, their use
is associatedwith a number of complications, notably capsular contraction, malposition, and anaplastic
large cell lymphoma.2,3 In a proportion of post-mastectomies, the use of implants is not possible due to
the irregularity of the soft tissue defects, particularly in post-radiotherapy patients.4 An alternative is
the employment of complex reconstructive techniques including deep inferior epigastric perforator
(DIEP) and latissimus dorsi (LD) ﬂaps, that have an inherent complication risk and longer recovery
periods.5 Although cell assisted lipotransfer (CAL) will not replace these procedures (due to the shape
and projection proﬁles they achieve), it has potential to serve as an adjunct for small corrections or
volume increases, and may serve as a less invasive option for patients hoping to achieve subtle
aesthetic enhancements. It should be noted that there is limited evidence to suggest that fat grafting
without the use of adipose derived stem cell supplementation can be used for complete post-
mastectomy reconstruction. This has, however, used a technique called BRAVA-assisted fat grafting
were an external volume expansion device is applied to enhance graft survival. For example, Khouri
2015 conducted a level IV study on 488 women (616 breast) and concluded that BRAVA-assisted fat
grafting is a minimally invasive, safe and economic alternative to other forms of breast reconstruction.6
The technique has also been used by the same study author to investigate the effect of large volume fat
grafting after BRAVA use or implant removal with positive results.7 Adipose derived stem cells, fat
grating and external volume expansion technology is therefore a potential area of future research,
speciﬁcally with regards to whole breast and large volume fat grafting.
An option for both breast augmentation and reconstruction is autologous fat grafting. Although
studies have reported a more natural breast contour, reports of fat resorption have been reported.8
Reported graft retention using this procedure vary from 40 to 75%, and therefore there is room for
improvement in the efﬁcacy of this procedure.9 It has been found that the key to fat graft retention is
maximizing the surface area to volume ratio, and the vascularity of the recipient area.10,11 Studies have
suggested that adipose derived stem cells can survive the period of hypoxia post surgery that is
thought to result in the necrosis of conventional fat.11 This provides scientiﬁc rational to using CAL in
breast surgery and is why the use of this technique can be seen as a key development in the repertoire
of techniques available to surgeons.12
CAL utilizes fat grafts that have been enriched with a patient's adipose derived stem cells (Figure 1
compares CAL to autologous fat transfer). Adipose derived stem cells are able to enhance both
angiogenesis and adipogenesis. Translating this into the clinical setting, it is hoped that long-term graft
retention and lower post-operative complication rates will result.13,14 The abundance of adipose tissue
Figure 1. The cell assisted lipotransfer procedure. Harvested fat is separated with approximately one half being used to harvest adipose derived stem cells and the other being processed for use as
a fat graft. The two constituents are then combined and placed within the recipient site. Note that the black arrows indicate the procedure for a conventional autologous fat transfer procedure.
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Z. Arshad et al. / JPRAS Open 10 (2016) 5e208makes the harvesting of these cells relatively easy, avoiding the need for in-vitro expansion.15 In
addition, the removal of fat from aesthetically sensitive anatomical regions offers secondary patient
beneﬁts.
Several clinical studies have assessed the use of CAL in breast surgery. However, there has been no
objective assessment of the evidence in this area. Limited examples of secondary research have been
published examining CAL for multiple indications,16,17 but no studies focus exclusively on breast-
related procedures. In light of this and the prospective role of CAL in breast augmentation and
reconstruction, this systematic review was conducted to assess the efﬁcacy and safety of cell assisted
lipotransfer in breast surgery. We also aimed to ascertain the quality of the completed studies with
particular consideration to methods of recruitment, appropriate follow-up and assessment of patient
reported outcomes. Through this, we aim to inform future clinical trial organizers of limitations of
current studies.
Methods
Search strategy
A systematic review was carried out according to the PRISMA guidelines,18 the details of which can
be found in Supplementary Material Document 1.
Results
Study selection
The literature and database searches identiﬁed 11 studies for inclusion (Figure 2 provides a detailed
breakdown of the search). The search of PubMed and Ovid yielded 3553 and 1825 studies, respectively.
Searches through the bibliographies of the identiﬁed articles and relevant publications resulted in the
addition of two further studies. A number of incomplete trials were identiﬁed from searches on clinical
trials registers that will be analysed separately in the discussion section of this paper.
Overview of studies
The 11 studies included (Table 1) comprised of 336 participants with follow-up times that were both
variable and occasionally inconsistent within the studies. They ranged from six months in Wang et al.
201519 and Peltoniemi et al. 201320 to 42 months in Yoshimura et al. 200812 (a single patient was
followed for this length of time). The majority of trials (n ¼ 9) were observational, with eight being
prospective and one retrospective with none being randomized. The further two studies comprised
one case study21 and one case series.12 Six studies looked into CAL for breast augmentation. Five
concerned the use of CAL in breast reconstruction to treat breast defects in patients undergoing
cosmetic, congenital and reconstructive procedures.
Patient demographic and operative details
All procedures carried out were single-stage procedures with no in-vitro expansion of the harvested
stem cells. Studies described a similar surgical technique utilizing initial stab incisions, cannula
insertion and subsequent injection of the fat graft into the breast in a multilayered and circular manner
to optimize distribution. Weighted mean age and BMI of participants were 42.7 (SD 7.15) years and
21.87 (SD 1.89) kg/m2, respectively. Weighted mean fat harvested was 691.77 (Standard Deviation¼ SD
339.25) ml. Weighted mean fat injected into the left and right breast was 253.65 (SD ¼ 20.05) and
265.51 (SD ¼ 14.15) ml, respectively. When volume injected into each breast was not disclosed per
breast this average was 174.97 (SD 63.69) ml/per breast. Fat was harvested from a number of
anatomical locations with a number of different systems being used to process the fat as detailed in
Table 2. Table 2 also summarizes data regarding cell count and viability within the fat grafts. A number
of studies recruited women of solely Asian heritage (Table 1).14,23,27,29,32
Figure 2. Search history following the PRISMA guidelines.
Z. Arshad et al. / JPRAS Open 10 (2016) 5e20 9Quality assessment
Figure 3a/b summarizes the bias assessment that was carried out. A large number of the studies
exhibited selection bias as they did not provide details regarding their recruitment process. Many
studies did not report the demographic of their patient cohort in detail for an assessment of whether
the results could be extrapolated to the general population. The criteria used to measure outcomes
were pre-speciﬁed and contained mostly objective methods of assessment but did include more
subjective assessments of patient/surgeon satisfaction. For example, in Kamakura et al. 2011,22 patients
were asked to select a satisfaction rating from the options: excellent, good or fair with no focus on
negative outcomes. Only three studies used comparison groups. In addition to this, one study Dos Anjos
et al. 201523 used a “sham control” where the comparison group received fat grafts that were enriched
with a low level of adipose stem cells that showed no advantage over conventional autologous fat
transfer. Three studies exhibited a high level of attrition bias: Yoshimura, et al. 2010,24 where 12month
data were collected for only six out of an original cohort of 15 patients and Peltoniemi et al. 2013,20
where two participants were excluded as their BMI had changed too much. In addition, when it was
realized that the intervention showed no advantage over conventional autologous fat transfer the
study was discontinued. In Domenis et al. 201525 data was not collected for seven out of 30 patients. In
a number of studies ﬁnancial conﬂicts of interest were not declared with one study author declaring
that he is an employee of Cytori Therapeutics (San Diego; USA): a regenerative-medicine company
developing cell-based therapies from adult adipose tissue.
Graft survival
A summary of graft survival outcomes and how they were measured in each study are presented in
Table 3. Jung et al. 2015,26 Wang et al. 201519 and Peltoniemi et al. 201320 all reported negative
Table 1
An overview of the included studies discussing key aspects such as study design, details regarding follow-up, conclusions and the main limitations of each trial.
Article ID Study design Intervention Country Follow-up details Main conclusions Use of validated PROMS and
patient reported outcomes
Calabrese
et al. 2009
Single patient
case study
Breast
reconstruction
Italy Aesthetic result measured
at 10 months; graft
retention at 3 months
and 17 month
oncological follow-up
Positive outcome/sufﬁcient and
reliable way to restore breast
volume with natural shape/no
post-operative complications/patient
evaluated results as excellent
No use of validated PROMS.
No explanation of how
information regarding patient
satisfaction was gathered.
Kamakura
et al. 2011
20 Japanese women
in prospective,
non-randomized
open label study
Breast
augmentation
Japan 9 months with check up
at 2 weeks and then
1, 3.6 and 9 months
Positive outcome/improvement in
baseline breast volume/method is
safe as no serious or adverse side
effects/physician and patient
satisfaction at 69% and 75%
respectively/cysts in two patients
No use of validated PROMS.
Patients were asked their
overall satisfaction with
treatment results in terms
of three possible responses:
excellent, good, or fair
Gentile
et al. 2015
50 patients (10 control)
in non-randomized
control trial
Breast
reconstruction
Italy 2, 7, 15, 21, and 36 weeks
and then annually
Positive outcome/statistically
signiﬁcant improvement in breast
contour and 3D volume/ultrasound
showed cysts in 45.83% of patients/
cytosteatonecrotic areas were
observed with ultrasound in
12.5%/no serious complications
No use of validated
PROMS e although there was
use of objective criteria to
measure patient satisfaction.
Wang et al. 2015 12 Chinese women
in open labelled
non-randomized study
Breast
augmentation
China 6 month follow-up with
one check up at 3 months
Mixed conclusion/the resorption of
grafted fat at the 6 months
post-operatively was 51.84% that
presents no statistical advantage over
existing techniques/cysts and nodules
were detected in 2 cases/no calciﬁcation
was found. Only 1 patient was unsatisﬁed
with cosmetic outcome. Study displayed
a satisfactory augmented volume with
little complications using CAL for
breast augmentation
No use of validated PROMS.
No explanation of how
information regarding patient
satisfaction was gathered.
Yoshimura
et al. 2008
Case series of 40
Japanese patients
Breast
augmentation
Japan 19 of the patients have
been followed for longer
than 6 months/longest
follow-up has been
42 months
Procedure is effective and safe/positive
cosmetic outcome/cysts in two
patients/two patients experienced
ﬁbrosis of breast and sternum/created
a more natural breast contour but lower
height than implant augmentation/all
patients were described as satisﬁed
No use of validated PROMS.
No explanation of how
information regarding patient
satisfaction was gathered.
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Jung et al. 2015 Prospective study
of 5 women
Breast
augmentation
Korea Follow-up at 3 months
and 1 year; will continue
to 2 years every 6 months
Negative as no apparent beneﬁt to
addition of SVF/oil cysts in 3 of the
10 breast/1 patients had nodule/only
about half of grafted volume was
present at 1 year/outcome better in
nulliparous women
No report of patient
reported outcomes.
Yoshimura,
et al. 2010
Prospective study of
15 Japanese women
Breast
augmentation
Japan 8 patients followed for
more than 12 months
with maximum
follow-up of 18 months
Positive/clinical results were
satisfactory/no major abnormalities
were seen on magnetic resonance
imaging or mammogram after
12 months/all patients
report satisfaction
No use of validated PROMS.
No explanation of how
information regarding patient
satisfaction was gathered.
Dos Anjos
et al. 2015
Retrospective,
non-randomized trial
including 74 women
Breast
reconstruction
Spain 7 dayse540 days
post-operatively
Final volume retention in the
long-term was higher with high
cell-enhanced fat grafts.
Complications include Mondor's
disease/9 cases of subcutaneous
benign lumps/oil cysts in 14 patients/
no intraoperative complications.
No report of patient
reported outcomes.
Peltoniemi
et al. 2013
Prospective controlled
study with 18 women
(8 controls)
Breast
augmentation
Finland 6 months Negative/no additional beneﬁt to
enrichment of graft SVF so not worth
increased cost and risk. 1 patient in
both control and intervention group
developed small cysts.
No use of validated PROMS.
No explanation of how
information regarding patient
satisfaction was gathered.
Perez-Cano
et al. 2012
Prospective trial
with 71 patients
Breast
reconstruction
Europe 12 months with
6 month check up
Positive/improvement of breast
contour in 54 cases/no serious
adverse events/no reported local
cancer recurrences/injection site
cysts in ten patients/50 patients and
57 investigators reported satisfaction/
subcutaneous bleeding following
liposuction and pelvic bone metastasis
Only study to use validated
PROMs. Used a number of
objective and subjective scales
to assess patient satisfaction
including Clough's classiﬁcation
system for breast reconstruction,
Late Effects Normal Tissues
(LENT)-Subjective Objective
Management Analysis scoring
system and a Quality of
Life assessment.
Domenis
et al. 2015
30 patients Breast
reconstruction
Italy 12 months with a
6 month check up
Patients treated with SVF enhanced
fat grafts demonstrated superior
outcomes/no mention of complication
No report of patient
reported outcomes.
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Table 2
This table provides a summary of operative details for each included study.
Article ID Number of
participants
Mean age
(years)
Mean BMI
(kg/m2)
SVF isolation method Cell count in graft Mean cell
viability (%)
Mean volume
harvested (ml)
Volume injected
(ml) (left breast/
right breast)
Site of fat harvest
Calabrese
et al. 2009
1 37 e Celution system e e 355 e Abdomen and
external thighs
Kamakura
et al. 2011
20 35.6 (range
21e52)
e Celution system 3.42  105 ±
1.39  105/g
85.3 ± 6.2 1026.5 (range,
660e1125)
235.1 ml (range
166e290)/
244.9 ml (range
166e330)
Thighs, hips, buttocks,
or abdominal area
Gentile
et al. 2015
50 Range 19e60 e Celution, Lipokit
Medikhan, Fatstem,
and Mystem systems
e 98 e 93.54 (range
50e150)
e
Wang
et al. 2015
12 32 (range
28e56)
22.10 Lipokit Medikhan
system
Nucleated cell
numbers
2.74 ± 1.07  107/g
e 750 256 (range
198e330)
Thighs, ﬂanks, and/
or lower abdomen
Yoshimura
et al. 2008
40 35.8 (range
20e62)
19.1 ± 1.9 e e e 1111.8 ± 164.0 268.1 ± 47.6/
277.3 ± 39.1
Thighs, abdomen
and lower legs
Jung
et al. 2015
5 34.4 ± 9.15 20.18 ± 2.84 e 34.76  106 ±
27.14  106
SVF cell count
e 574.4 ± 152.58 196.2 ± 49.69/
246.2 ± 62.99
e
Yoshimura,
et al. 2010
15 37.1 ± 12.5 19.5 ± 1.4 e e e e 259 ± 39/
268 ± 29
e
Dos Anjos
et al. 2015
74 38.58 21.58 GID SVF-1 device 5.83  105 ±
2.88  105/ml
82.79 ± 8.14 249.9 Infraumbilical
area and ﬂanks
Peltoniemi
et al. 2013
18 51 (range
29e58)
23.4 (range
20.3e32.5)
Celution system e e e 177 (range
122e298)/180
(range 122e258)
Perez-Cano
et al. 2012
71 52 (37e68) 24.5 (range
17e31)
Celution system 2.95  105 stromal
vascular cells per ml
86.6 364 (range
223e570)
140 (range
35e250)
Domenis
et al. 2015
30 48 (19e74) 21.4 (19.8e
32.8)
Celution, Lipokit
Medikhan, Fastem
Corios system
e e e e Abdomen, hips, and
trochanteric area
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Figure 3. a/b e Risk of bias summary: review authors' judgements about each risk of bias item for observational studies.
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Table 3
A summary of the graft volume retention and how it was measured.
Article ID Number of
participants
Breast/graft volume measurement method Result
Calabrese et al. 2009 1 Graft retention in mastectomy ﬂap evaluated with MRI and
ultrasound at 3 months.
Patient evaluation as excellent,
surgeon as good
Kamakura et al. 2011 20 Measured change in breast size (BRM) e circumferential breast (B) and
circumferential chest (C) were measured and subtracted through
physical examination to calculate this.
BRM on average increased by 3.3 cm
Gentile et al. 2015 50 patients
(10 control)
3 Methods used: team evaluation, MRI and USS, patient self evaluation. 49.25% of volume maintained on average
in intervention group vs. 39% in control
Wang et al. 2015 12 MRI, 3T whole body scanner, 3 radiologists. Resorption rate at 6 months from
19.99% to 71.22%, mean 51.84%
Yoshimura et al. 2008 40 Breast circumference (chest circumference at the nipple minus the
chest circumference at the inframammary fold) was measured through
physical examination.
Circumference increase 100e200 ml
after injection of 270 ml
Jung et al. 2015 5 Breast volume determined by volume rendering technique, using MRI.
Each breast outlined anteromedially along inner surface of skin and
posteriorly along the anterior surface of pectoral muscle.
One year after CAL, breast had decreased
to 47% of initial post-operative volume
Yoshimura, et al. 2010 15 Mammography, MRI, photography, videography and 3D measurements,
to allow for volumetric evaluation of breast mound.
Right mean 155 ± 50 ml
Left mean 143 ± 80 ml
At 12 months
Graft take ranged from 40 to 80%
Dos Anjos et al. 2015 74 3D imaging scan utilized to quantify volume changes. ARTEC
MHT 3D scanner, superimposed to measure difference.
Scans Pre and post LD volume.
75% and 50% breast volume retention
in high and low SVF cell enrichment
groups, respectively
Peltoniemi et al. 2013 18 women
(8 controls)
MRI scans before and 6 moths after surgery to exclude complications.
Volume analysis performed by a blinded independent examiner.
54% graft survival in control group and
50% in intervention group
Perez-Cano et al. 2012 71 T1 weighted MRI at baseline, 6 and 12 months post index treatment.
Scored by 2 independent radiologists blinded to patient sequence
using 5 point Likert Scale for breast defect and contour.
57 of 67 patients reported satisfaction.
Independent radiographic core laboratory
assessment reported improvement in the
breast contour of 54 out of 65 patients
based on blinded assessment of
MRI sequence
Domenis et al. 2015 30 (16 control) USS measurement of subcutaneous thickness in reconstructed breast
acquired preoperatively, 6e12 months post op.
Patients treated with SVF enhanced
grafts demonstrated at 6 months a
signiﬁcant superior gain of thickness
of both central and superior medial
quadrants with respect to patients
treated with standard lipotransfer
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Z. Arshad et al. / JPRAS Open 10 (2016) 5e20 15outcomes in terms of graft volume. Jung et al. 201526 described a 43% decrease in breast volume, a
ﬁgure similar to that seen in conventional autologous fat grafting. Peltoniemi et al. 201320 is one of
three studies that includes a comparison group and found that graft retention in its intervention group
was 50% compared to 54% in the control e although there was no statistical difference between the
two. Two of the largest studies, Gentile et al. 201527 (n ¼ 50) and Dos Anjos et al. 201523 (n ¼ 74),
reported positive and statistically signiﬁcant results. Gentile et al. 201527 found an average graft
retention of 49.25% using CAL vs. 39% in its control group and represents the second study incorpo-
rating a control group. Dos Anjos et al. 201523 reported an average graft retention of 75% when using
grafts that were high in their stem cell content compared to 50% in the group of patients that received
low stem cell enriched grafts in what the authors describe as a ‘sham control group’. Domenis et al.,25
the ﬁnal controlled trial, found graft retention to be better in its cell enriched group also e however,
this measurement was made though ultrasonography. In all other studies, authors report positive
ﬁndings although no comparison group was present, and the quantitative data presented does not
indicate any meaningful advantage over existing techniques.27 Methods of measuring graft volume
retention (summarized in Table 3) varied between studies and the case study by Calabrese et al. 200921
did not report any quantitative measurement of this outcome. The majority of studies used magnetic
resonance imaging (MRI) due to its reliability and accuracy inmeasuring graft volume,28 however a few
studies opted for physical measurements (e.g. breast circumference). Yoshimura, et al. 201024 and Dos
Anjos et al. also used 3D measurement techniques.
Complications
The complications that occurred during the course of each study are presented in Table 4. The
overall complication rate across studies was 37%, with the most common side effect being calciﬁcation
e comprising 83% of all complications. Fibrosis, and consequent hardening of the breast, was seen in a
single case by Yoshimura et al. 200824 and an isolated case of Mondor's disease (a rare condition thatTable 4
Complications that occurred during the course of each study. It should be noted that each complication was considered to be an
independent event as information regardingmultiple complications in single patients was not available. Calciﬁcation is by far the
most commonly cited complication using CAL. Note that no information regarding complications was reported in Domenis et al.
2015.
Article ID Number of
participants
Cysts Calciﬁcation Cancer occurrence Operative
complications
Other complications
Calabrese
et al. 2009
1 None None None None None
Kamakura
et al. 2011
20 2 2 None None Fat necrosis
Gentile
et al. 2015
50
(10 control)
23 None None None Cytosteatonecrotic
areas in 6 patients
Wang
et al. 2015
12 2 None None None Swelling and
ecchymosis for one
month/2 nodules
Yoshimura
et al. 2008
40 2 2 None None Fibrosis of sternum
and breast tissue
Jung
et al. 2015
5 3 None None None 1 nodule
Yoshimura,
et al. 2010
15 None None None None None
Dos Anjos
et al. 2015
74 14 None None None Mondor's disease
in one patient
Peltoniemi
et al. 2013
18
(8 controls)
1 None None e None
Perez-Cano
et al. 2012
71 10 (46 sub-
clinical)
None Yes (pelvic
bone metastasis)
Five serious adverse
events including
subcutaneous bleeding
following liposuction.
None
Z. Arshad et al. / JPRAS Open 10 (2016) 5e2016leads to thrombophlebitis of the superﬁcial veins of the breast and anterior chest wall29) was reported
by Dos Anjos et al. 2015.23 Five serious adverse effects were reported either during or immediately
post-procedure by Perez-Cano et al. 201230 e but only two of these were described. They comprised of
subcutaneous bleeding, which was thought to be due to the post-operative use of anti-coagulants, and
bony metastasis; secondary to natural disease progression.Patient reported outcomes
Validated PROMswere only used in a single study.30 The study, by Perez-Cano et al. 2012, represents
the most comprehensive assessment of PROMs and used a number of objective scales to assess patient
satisfaction. This included Clough's Classiﬁcation System for breast reconstruction, the Late Effects
Normal Tissues (LENT)-Subjective Objective Management Analysis scoring system and a Quality of Life
assessment. Overall, at 12 months, 58 out of 67 surgeons and 45 out of 67 patients were reportedly
‘satisﬁed’ with aesthetic outcomes, and 57 out of 67 surgeons and 50 out of 67 patients reported
satisfaction with regards to the whole treatment process, when taking into account all of the assess-
ment methods used. Quality of life scores remained constant throughout the follow-up period. Three
studies did not report any measure of patient reported outcomes (See Table 1). Of the studies that did
report patient reported outcomes, the methods for data collection were not stated. For example, in the
study by Calabrese et al. 2009,21 the patient reportedly stated their outcome as ‘excellent’ with no
accompanying explanation of how this was justiﬁed. This also occurred in the study by Kamakura et al.
2011,22 where 75% of patients were reportedly ‘satisﬁed’ with outcomes. Wang et al. 2015,19 reported a
single ‘unsatisﬁed’ patient and Yoshimura et al. 200812 reported that ‘most patients were satisﬁed with
their enlarged and soft breasts with a natural contour’ e and the surgeons also described the results as
‘generally satisfactory and encouraging’. When patients were asked if they would undergo repeat
procedures, Peltoniemi et al. 201320 reported that one patient answered ‘no’ and a further two were
‘unsure’ but offered no further justiﬁcation of these responses.
The outcome assessment conducted by Gentile et al. 201527 was based on objective criteria
examining ﬁve outcomes, including:
(1) Presence of asymmetry, deformity, irregularity, dyschromia, dysaesthesia, paraesthesia, and
pain;
(2) Results of the superoexternal quadrant, inferoexternal quadrant, superointernal quadrant, and
inferointernal quadrant;
(3) Resorption of fat in one or more regions;
(4) Time of stabilization of the transplanted fat; and
(5) Need for retreatment.
Patients provided a yes/no or positive/negative evaluation in addition to a percentage value. All
patients reported satisfaction with texture, softness and contour. A detailed breakdown incorporating
all the outcomes assessed above was not provided.
Generally, the provision of patient reported outcomes in the studies identiﬁed was poor. Future
studies, therefore, should only use validated PROMs such as the BREAST-Q that are used appropriately
and time-critically. This will generate moremeaningful patient insights and facilitate amore consistent
degree of comparability between studies.
For additional analysis please see Supplementary Material Document 2.
Discussion
Due to the infancy of this technique in breast augmentation and reconstruction, the current level of
evidence surrounding CAL makes it difﬁcult to draw conclusions for its use in the clinical setting. The
majority of studies included in this review are positive in relation to graft retention, complication rates
and patient or surgeon reported outcomes. However, there is a lack of methodological rigour e the
absence of control groups in eight out of the 11 studies makes it difﬁcult to ascertain the efﬁcacy and
Z. Arshad et al. / JPRAS Open 10 (2016) 5e20 17safety of CAL. In addition, one of the three studies20,25 that made use of a control group found no
statistical advantage in using CAL in contrast to the other two controlled studies25,27 that did ﬁnd a
difference. Evidently, further work is needed to assess the full effect, if any, of CAL for this indication.
Peltoniemi et al. 201320 highlighted that the conventional autologous fat transfer procedure takes
around 90e150 min less time in addition to being $3000 cheaper than CAL. Any beneﬁts that CAL may
bring need to be weighed against such drawbacks.
One of the key limitations that this systematic review highlights is the short follow-up times that
are insufﬁcient to assess the long-term implications of using CAL. This is of particular concern as pre-
clinical studies have shown the use of stem cell enriched autologous fat to increase rates of local cancer
occurrence31 and metastasis.32 We also found that calciﬁcation was the second most common
complication of CAL, occurring in four out of 336 patients. Although in all cases this calciﬁcation was
found not to be of malignant origin, the presence of calciﬁcation may lead to false positive results on
mammography causing undue stress e this can be mitigated through use of expert radiologists who
can readily distinguish malignancy from fat changes in the context of fat grafting.33
The ﬁeld of plastic surgery is widely adopting the use of quality of life measures.34,35 Although the
majority of studies did acknowledge patient satisfaction e the methodology was generally not
described and as such, their reliability is limited. Most notably, in Kamakura et al. 2011,22 patients were
questioned about their satisfaction with their treatment outcomes in terms of three possible re-
sponses: excellent, good, or fair, with no option to report any potential negative outcomes e
demonstrating a considerable element of bias. Therefore, the use of validated PROMs, such as BREAST-
Q, should be routinely utilized. These validated PROMs are superior to conventional methods of col-
lecting patient reported outcomes and are considered reliable (in that theymeasure how the procedure
has inﬂuenced the patient and not any other factor), valid (in that they are objective inwhat they intend
tomeasure) and sensitive (in their ability to detect change in a patient).36,37 The use of suchmeasures is
therefore twofold: ﬁrstly, this would allow a consistent measure of satisfaction and well-being that
could be compared between studies to collect relevant information while minimizing bias; secondly,
BREAST-Q covers a broad range of domains including psychosocial, physical and sexual well being in
addition to satisfaction with breasts, care and outcome and how this relates to the patients expecta-
tions.38 In doing so, reliable data could be pooled to take a more patient centred approach to improving
CAL. It could also provide insight into patient understanding of the procedure including its limitations
to foster improvement in the acquirement of informed consent.
To assess the current clinical trial landscape, active clinical trials involving CAL in breast-related
procedures were identiﬁed through searches of relevant clinical trial registries (see Figure 4). In
total, 15 active studies were identiﬁed e the majority in early stages of translation (9 in phase two
clinical trials). This is in line with what would be expected for an intervention in the early stages of
development. In contrast to the studies previously mentioned, a signiﬁcant proportion of the trials
already have or are planning to recruit large numbers of participants, with the largest aiming for 440.
Whether this is achievable is open for debate but may offer an explanation as to why such a signiﬁcant
proportion (60%) are still in the recruitment stage. Six out of the 15 future trials intend to use a
comparison group, for more rigorous data analysis into the effects of CAL in breast reconstruction or
augmentation. Our systematic review highlighted inadequate trial follow-up times and a failure to
address long-term outcomes, particularly surrounding the risk of malignancy. This is a major concern
for both patients and clinicians and will likely dictate the viability of the procedure and its potential for
universal application in breast-related and other procedures.
Limitations
Limitations of this study include the small sample of patients (n ¼ 336) and the high levels of se-
lection bias found within the studies. Only three of the studies included control groups, making it
difﬁcult to compare CAL to conventional autologous fat grafting. Follow-up times varied within studies
and were too short to detect long-term outcomes of interest e notably the risk of malignancy. The
studies also employed heterogeneous methods to measure graft survival with a corresponding lack of
validity regarding the methods of assessing patient satisfaction levels post-operatively. In addition, a
number of studies failed to declare ﬁnancial conﬂicts of interest and in one study an author declared
Figure 4. The majority of studies are still in the early stages of translation in an attempt to ascertain the efﬁcacy and safety of the
procedure (a) and a major proportion of the trials plan on recruiting a larger number of participants (Note sample number unknown
for one study) (b). An increasing number of trials plan on employing comparison groups especially for breast reconstruction (Note
that some trials are investigating CAL for both breast augmentation and reconstruction so these are shown separately in this ﬁgure)
(d). On the contrary future trials still fail to show a follow-up time long enough to demonstrate long-term effects (c).
Z. Arshad et al. / JPRAS Open 10 (2016) 5e2018himself an employee a company developing cell-based therapies from adult adipose tissue. The large
degree of heterogeneity meant that a meta-analysis to calculate the true effect size of cell assisted
lipotransfer for the outcomes of interest discussed within this systematic review was not feasible.
Conclusion
The literature indicates that CAL may be a promising surgical technique. Presently, studies
demonstrate high levels of bias, lack control groups and display considerable heterogeneity, making
the generalizability of study results and effect size unclear. Furthermore, lack of long-term follow-up
data and associated concerns of malignant risk require mitigation. Further rigorous randomized
controlled trials are needed to investigate the procedure's full clinical efﬁcacy and safety proﬁle that
should also make use of validated PROM's.
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